Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850
This study is recruiting at 4 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- mCRPC
- Urogenital Neoplasms
- Prostatic Neoplasms
- Prostatic Diseases
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Blue Earth Therapeutics Ltd
- Last updated on ClinicalTrials.gov
- May 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- Biogenix Molecular LLC · Miami, FL
- NovaCure Health · Miami, FL
Georgia · 1
- Emory University Hospital · Atlanta, GA
Nebraska · 1
- XCancer Omaha / Urology Cancer Center · Omaha, NE
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.